ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 8, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 8, 2011
News
FDA Issues Letter to Pfizer Regarding Violative Online Marketing
By Angie Drakulich
FDA's Division of Drug Marketing, Advertising, and Communication issued a letter to Pfizer's vice-president of US Regulatory Affairs regarding its online resources page for Lipitor tablets.
Generic Drug User Fee Agreement Nears Completion
By Amy Ritter
Representatives from FDA, the Generic Pharmaceutical Association, the European Fine Chemicals Group, and a task force from the Society of Chemical Manufacturers and Affiliates are nearing completion of draft legislation for the Generic Drug User Fee Act.
Sanofi Outlines Long-Term Objectives
By Patricia Van Arnum
Sanofi outlined its long-term financial objectives this week as the company discussed its strategy in mitigating generic-drug incursion and in generating growth in key therapeutic areas and emerging markets.
Pfizer Completes Tender Offer For Icagen
By Stephanie Sutton
Pfizer has completed its cash tender offer for the biopharm company Icagen after extending its initial deadline.
Week of September 5, 2011: GSK, Anacor Expand R&D Collaboration; Xoma Announces Management Changes; and More
GSK, Anacor Expand R&D Collaboration; Xoma Announces Management Changes; and More.
Regulatory Roundup: USP Expands Presence in India
USP Expands Presence in India.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here